{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-18T17:18:42.925653+00:00","company":{"ticker":"ALDX","cik":1341235,"company_name":"Aldeyra Therapeutics, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"AbbVie Inc.","detail":"collaboration","count":1,"first_seen":"2023-11-01T23:59:59+00:00","last_seen":"2023-11-01T23:59:59+00:00","evidence_fact_ids":[100185]}]},"facts":[{"fact_type":"executive_change","fact_key":"95f7c49c68","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-06-10T00:30:15+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-09","interim":false,"role":"Class III director and Chair of the Audit Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"Darlene Deptula-Hicks was appointed as Class III director and Chair of the Audit Committee at Aldeyra Therapeutics, Inc..","evidence_excerpt":"the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial term expiring at the Company’s 2029 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-264514","anchor_url":"https://secwatch.observer/filing/0001193125-26-264514#claim-95f7c49c68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4f933154cc799329dd9be39bb71f23cb84d2a68c","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-06-10T00:30:15+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-09","outcome":"passed","proposal_text":"Advisory vote on compensation of named executive officers (non-binding)","proposal_type":"say_on_pay","results":[{"broker_non_votes":"20,038,067","subject":null,"votes_abstain":"87,138","votes_against":"4,543,221","votes_for":"19,477,504","votes_withheld":null}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers (non-binding) at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 3: Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 19,477,504 4,543,221 87,138 20,038,067","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-264514","anchor_url":"https://secwatch.observer/filing/0001193125-26-264514#claim-4f933154cc799329dd9be39bb71f23cb84d2a68c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm"},{"fact_type":"shareholder_vote","fact_key":"96736b1c632062497739eb5b4ff52437d6bf83c5","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-06-10T00:30:15+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-09","outcome":"passed","proposal_text":"Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"130,657","votes_against":"321,501","votes_for":"43,693,772","votes_withheld":null}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,693,772 321,501 130,657","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-264514","anchor_url":"https://secwatch.observer/filing/0001193125-26-264514#claim-96736b1c632062497739eb5b4ff52437d6bf83c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm"},{"fact_type":"shareholder_vote","fact_key":"780f6f5ce2ab67d110b0b52926b62966ab2087f6","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2026-06-10T00:30:15+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-09","outcome":"passed","proposal_text":"Election of one director to serve as a Class III director","proposal_type":"director_election","results":[{"broker_non_votes":"20,038,067","subject":"Todd C. Brady, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"23,026,101","votes_withheld":"1,081,762"}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Election of one director to serve as a Class III director at the 2026-06-09 meeting.","evidence_excerpt":"Proposal 1: Election of Directors. The Company’s stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders or until his successor is duly elected and qualified or until earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 23,026,101 1,081,762 20,038,067","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-264514","anchor_url":"https://secwatch.observer/filing/0001193125-26-264514#claim-780f6f5ce2ab67d110b0b52926b62966ab2087f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm"},{"fact_type":"executive_change","fact_key":"3a7be6c82a","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2025-04-17T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-17","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William (Chip) Clark was elected as Director at Aldeyra Therapeutics, Inc..","evidence_excerpt":"the Board elected William (Chip) Clark as a Class I director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-032947","anchor_url":"https://secwatch.observer/filing/0001213900-25-032947#claim-3a7be6c82a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000121390025032947/0001213900-25-032947-index.htm"},{"fact_type":"executive_change","fact_key":"27b4b2518c","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-31","interim":false,"role":"principal financial officer and principal accounting officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Michael Alfieri was appointed as principal financial officer and principal accounting officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"On August 29, 2024, the board of directors of Aldeyra Therapeutics, Inc. (the “Company”) approved the appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer effective as of August 31, 2024 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-211645","anchor_url":"https://secwatch.observer/filing/0001193125-24-211645#claim-27b4b2518c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm"},{"fact_type":"executive_change","fact_key":"72825c376b","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-31","interim":true,"role":"Senior Vice President of Finance, Interim Chief Financial Officer","role_category":"other_named_officer","successor_name":"Michael Alfieri","successor_named":true},"claim":"Bruce Greenberg departed as Senior Vice President of Finance, Interim Chief Financial Officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"As previously disclosed by the Company, Bruce Greenberg stepped down from his positions with the Company, including as the Company’s Senior Vice President of Finance, Interim Chief Financial Officer and principal financial officer and principal accounting officer as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-211645","anchor_url":"https://secwatch.observer/filing/0001193125-24-211645#claim-72825c376b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm"},{"fact_type":"material_agreement","fact_key":"bd11b9fa5277e90b0ca5b571a923507fe6abd873","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Option Agreement","agreement_type":"collaboration","counterparty":"AbbVie Inc.","effective_date":"2023-10-31","item_codes_triggered":["1.01"],"value_text":"$1 million"},"claim":"Aldeyra Therapeutics, Inc. entered into Option Agreement with AbbVie Inc. valued at $1 million (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023 (the “Effective Date”), Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into an exclusive option agreement (the “Option Agreement”) with AbbVie Inc. (“AbbVie”)","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001193125-23-267697","anchor_url":"https://secwatch.observer/filing/0001193125-23-267697#claim-bd11b9fa5277e90b0ca5b571a923507fe6abd873","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/0001193125-23-267697-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e554d8baa4cee67fb6cdb90e2adf6f05d8f902d4","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-30","outcome":"passed","proposal_text":"Approval of the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"15,106,765","subject":null,"votes_abstain":"54,590","votes_against":"1,293,014","votes_for":"27,066,030","votes_withheld":null}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Approval of the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan at the 2023-06-30 meeting.","evidence_excerpt":"Proposal 4:            Approval of the Adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan. The Company’s stockholders approved the adoption of the Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,066,030 1,293,014 54,590 15,106,765","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-181344","anchor_url":"https://secwatch.observer/filing/0001193125-23-181344#claim-e554d8baa4cee67fb6cdb90e2adf6f05d8f902d4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ec726d04261e85a50b37760ae3544c02fc39d1de","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-30","outcome":"passed","proposal_text":"Non-binding, advisory vote on the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"15,106,765","subject":null,"votes_abstain":"57,323","votes_against":"646,060","votes_for":"27,710,251","votes_withheld":null}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-30 meeting.","evidence_excerpt":"Proposal 3:            Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,710,251 646,060 57,323 15,106,765","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-181344","anchor_url":"https://secwatch.observer/filing/0001193125-23-181344#claim-ec726d04261e85a50b37760ae3544c02fc39d1de","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6b37f0518b94e00f844ed29734f629232132adb4","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-30","outcome":"passed","proposal_text":"Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"20,534","votes_against":"25,820","votes_for":"43,474,045","votes_withheld":null}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-30 meeting.","evidence_excerpt":"Proposal 2:            Ratification of Appointment of BDO USA, LLP. The Company’s stockholders ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,474,045 25,820 20,534","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-181344","anchor_url":"https://secwatch.observer/filing/0001193125-23-181344#claim-6b37f0518b94e00f844ed29734f629232132adb4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0b7d20ac4bf4f5368aa6686e1ca35138a6c19705","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-30","outcome":"passed","proposal_text":"Election of two directors to serve as Class III directors until the Company’s 2026 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"15,106,765","subject":"Todd C. Brady, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"21,007,679","votes_withheld":"7,405,955"},{"broker_non_votes":"15,106,765","subject":"Martin J. Joyce, M.B.A.","votes_abstain":null,"votes_against":null,"votes_for":"16,126,225","votes_withheld":"12,287,409"}]},"claim":"Aldeyra Therapeutics, Inc. shareholders approved Election of two directors to serve as Class III directors until the Company’s 2026 annual meeting at the 2023-06-30 meeting.","evidence_excerpt":"Proposal 1:            Election of Directors. The Company’s stockholders elected the following directors to serve as Class III directors until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 21,007,679 7,405,955 15,106,765 Martin J. Joyce, M.B.A. 16,126,225 12,287,409 15,106,765","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-181344","anchor_url":"https://secwatch.observer/filing/0001193125-23-181344#claim-0b7d20ac4bf4f5368aa6686e1ca35138a6c19705","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523181344/0001193125-23-181344-index.htm"},{"fact_type":"earnings_release","fact_key":"b375a2dbf25cd7db4980971a7a69564b6682645d","cik":1341235,"ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":null},"claim":"Aldeyra Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) issued a press release (the “Press Release”) regarding its financial results for the quarter ended March 31, 2023 and recent corporate highlights.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001157523-23-000722","anchor_url":"https://secwatch.observer/filing/0001157523-23-000722#claim-b375a2dbf25cd7db4980971a7a69564b6682645d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm"}]}